Recognizing adverse drug reactions is a core clinical competency for the COA. Every medication used in an ophthalmology clinic — from topical anesthetics and dilation agents to antibiotics, glaucoma drops, and diagnostic dyes — carries a profile of potential local and systemic adverse effects. The COA is often the first clinician to notice a patient reporting or displaying a drug reaction, making prompt recognition and escalation to the physician critical.
The COA exam tests knowledge of local reactions (allergic vs toxic conjunctivitis), the systemic absorption pathway through the nasolacrimal duct, specific systemic risks from common ophthalmic drugs (especially timolol), and the reaction risk profile for fluorescein angiography. Understanding these reactions — and the measures to prevent or minimize them — is both exam-critical and clinically essential.
Local Reactions: Allergic vs Toxic Conjunctivitis
Local adverse reactions to ophthalmic drugs predominantly affect the conjunctiva and cornea. The two main patterns — allergic (hypersensitivity) and toxic (chemical irritant) — have different clinical presentations, mechanisms, timelines, and management approaches. Correctly distinguishing them guides whether to discontinue the drug or simply change formulations.
| Feature | Allergic Conjunctivitis | Toxic Conjunctivitis |
|---|---|---|
| Mechanism | Immune-mediated (IgE or T-cell) | Direct chemical irritation (not immune) |
| Timing | After weeks–months of sensitization | Can occur quickly; correlates with use duration |
| Conjunctival reaction | Papillae (flat-topped, round, vascular) | Follicles (round, avascular lymphoid nodules) |
| Location | Superior tarsal conjunctiva (papillae); periorbital dermatitis | Inferior palpebral conjunctiva / inferior fornix (follicles) |
| Cornea | May have superior punctate staining | Punctate epithelial erosions (PEE) |
| Symptoms | Itching, tearing, chemosis, lid swelling | Burning, stinging, redness, discharge |
| Common causes | Brimonidine (10–15%), neomycin (high rate), thimerosal | BAK preservative, aminoglycosides (extended use), topical anesthetics (chronic) |
| Management | Discontinue offending drug; switch drug class if possible; antihistamine | Reduce frequency; switch to preservative-free formulation; consider drug holiday |
BAK (Benzalkonium Chloride) Toxicity
Benzalkonium chloride (BAK) is the most common preservative in topical ophthalmic solutions. It disrupts the lipid layer of the tear film and is directly toxic to corneal and conjunctival epithelial cells in a dose- and frequency-dependent manner. Patients on multiple preserved drops (common in glaucoma management) accumulate significant daily BAK exposure, leading to chronic toxic conjunctivitis, punctate epithelial erosions, and destabilization of the tear film. Management includes switching to preservative-free formulations (widely available for most glaucoma drugs), reducing the total number of drops through fixed-combination agents, and adding preservative-free artificial tears.
Periocular Contact Dermatitis
Contact dermatitis of the eyelid skin is a delayed hypersensitivity (Type IV, T-cell mediated) reaction to topical ophthalmic medications or their preservatives. It presents as eczematous lid and periorbital skin changes: erythema, scaling, fissuring, and thickening of the eyelid skin. The patient typically notes increasing itching and burning around the eye. Neomycin (present in combination antibiotic ointments like Neosporin) is one of the most common sensitizing agents. Brimonidine, thimerosal (older preservative), and propylene glycol can also cause contact dermatitis. Management: discontinue the offending agent, patch testing if unsure of the sensitizer, topical mild steroid (physician-prescribed) for acute symptoms.
Systemic Absorption Via the Nasolacrimal Duct
A commonly underappreciated pharmacological fact is that topical eye drops can cause significant systemic effects through nasolacrimal drainage and nasal mucosal absorption. When a drop is instilled, the patient blinks, and approximately 75–80% of the drop volume drains via the puncta into the canaliculi, lacrimal sac, and nasolacrimal duct, emptying onto the nasal mucosa beneath the inferior turbinate. The nasal mucosa has a rich blood supply and absorbs drugs directly into the systemic circulation, completely bypassing first-pass hepatic metabolism. This pharmacokinetic pathway is why such small topical doses can produce significant systemic effects.
Technique 1
Punctal Occlusion
Press inner canthus for 2 minutes after instillation. Physically blocks nasolacrimal drainage. Most effective technique for reducing systemic absorption by up to 70%.
Technique 2
Eyelid Closure
Close the eye gently for 2 minutes after instillation. Reduces blinking-driven nasolacrimal drainage. Nearly as effective as punctal occlusion and easier for patients.
Technique 3
Single Drop Instillation
The eye can hold approximately 7–10 µL of fluid; a standard drop is 30–50 µL. Using only one drop reduces the volume available for systemic absorption. Excess runs onto skin (not into the eye).
Timolol: Systemic Cardiovascular and Pulmonary Effects
Timolol maleate 0.5% ophthalmic drops are one of the most common sources of clinically significant systemic drug effects from topical ophthalmic therapy. Timolol is a non-selective beta-adrenergic blocker (blocks both beta-1 and beta-2 receptors). After nasolacrimal absorption, plasma concentrations sufficient to produce cardiovascular and pulmonary effects can be achieved in susceptible patients.
Pulmonary: Bronchospasm
Beta-2 receptor blockade in bronchial smooth muscle → bronchoconstriction. Can trigger severe, life-threatening bronchospasm in asthma and COPD. Contraindicated in all forms of reactive airway disease. Even cardioselective betaxolol has some risk.
Cardiac: Bradycardia and Heart Block
Beta-1 receptor blockade → reduced sinoatrial node firing rate → bradycardia (can reduce resting HR by 6–8 bpm). Can cause second- or third-degree heart block in predisposed patients. Contraindicated in sinus bradycardia (HR < 60), heart block (grade > 1), and cardiogenic shock.
Masking Hypoglycemia Symptoms
Beta-blockade blunts the tachycardia that warns diabetic patients of hypoglycemia. Patients on insulin who develop timolol-induced beta-blockade may fail to notice dangerous drops in blood glucose.
CNS Effects
Depression, fatigue, sexual dysfunction, and sleep disturbances have been reported with timolol eyedrops. CNS penetration is higher with lipophilic beta-blockers. Timolol is moderately lipophilic. These effects are often overlooked as a drug cause when patients report them in history.
Fluorescein Angiography Adverse Reactions
Fluorescein sodium is injected intravenously for fluorescein angiography (FA) to image retinal and choroidal blood vessels. The dye is relatively safe, but adverse reactions can occur and range from mild and self-limiting to life-threatening anaphylaxis. The COA may assist with FA procedures and must know the reaction profile and emergency preparedness requirements.
| Severity | Reactions | Approximate Frequency | Management |
|---|---|---|---|
| Mild | Nausea, vomiting, transient skin/urine discoloration | ~5% | Reassurance; position for comfort; usually self-limiting |
| Moderate | Urticaria, pruritus, sneezing, vasovagal syncope | ~0.5–1% | Antihistamine (diphenhydramine); physician evaluation |
| Severe / Anaphylactic | Bronchospasm, laryngeal edema, hypotension, cardiac arrest | ~1 in 200,000 | Epinephrine 1:1000 IM/IV; call 911; CPR if needed; physician leads resuscitation |
Emergency Preparedness for Fluorescein Angiography
Before every FA procedure, emergency equipment must be confirmed to be immediately available and functional:
- Epinephrine 1:1000 (0.3 mL for adult IM injection)
- Oxygen supply with mask
- Diphenhydramine (Benadryl) for moderate reactions
- IV access equipment (in case needed rapidly)
- Emergency call system / crash cart location known
- Emergency contact numbers (911) posted in FA suite
Steroid Complications: Cataracts, IOP, and Infection Masking
IOP Elevation (Steroid Response)
Approximately 30% of the general population shows IOP elevation with topical steroids ("steroid responders"). The response is even higher in patients with pre-existing glaucoma (up to 90%). Mechanism: steroids increase deposition of glycosaminoglycans in the trabecular meshwork, reducing aqueous outflow. IOP must be checked at every visit during steroid therapy. Stopping the steroid typically reverses the IOP rise over days to weeks.
Posterior Subcapsular Cataracts (PSC)
Chronic steroid use (topical, periocular injections, or systemic) causes posterior subcapsular cataracts — a specific lens opacity pattern located at the posterior lens capsule under the visual axis. PSC cataracts are vision-degrading and irreversible; the only treatment is cataract surgery. Risk increases with dose and duration. Inform patients that long-term steroid use carries this risk.
Infection Masking
Corticosteroids suppress the inflammatory response that signals active infection. Using steroids on an undiagnosed herpetic epithelial keratitis suppresses pain and redness while the virus continues to destroy the stroma — the result can be corneal perforation. Using steroids on undiagnosed fungal keratitis is equally catastrophic. The clinical rule: confirm there is no active infection (particularly viral or fungal) before initiating steroid therapy. If uncertain, a physician must evaluate before prescribing steroids.
Drug-Induced Color Changes
Several ophthalmic drugs cause visible color changes that the COA should recognize and explain to patients as expected drug effects rather than alarming side effects.
Iris Darkening — Prostaglandin Analogs
Latanoprost, bimatoprost, and travoprost increase melanin synthesis in iris melanocytes. In hazel or mixed irides, this causes irreversible darkening of the iris (the brown pigment component spreads). Patients must be warned before starting prostaglandins that iris color change is permanent — the iris does not revert if the drug is stopped.
Skin and Urine Discoloration — Fluorescein
After IV fluorescein angiography, patients experience transient yellowing of the skin and sclera, and bright orange-yellow urine for 24–48 hours. This is expected and harmless. Patients should be warned before the procedure to avoid alarm.
Corneal Verticillata — Netarsudil (ROCK Inhibitor)
Netarsudil can cause whorl-like deposits in the corneal epithelium (verticillata). These are visible on slit lamp examination and are usually asymptomatic. They resolve on drug discontinuation. Amiodarone, chloroquine, and hydroxychloroquine also cause corneal verticillata — the pattern is not unique to netarsudil.
Documenting Adverse Drug Reactions
Required Documentation Elements
- Date and time of reaction
- Drug name, concentration, and route (topical drops, IV injection, etc.)
- Reaction description: symptoms, signs, severity (mild/moderate/severe)
- Action taken: drug discontinued? Switched to alternative? Physician notified? Emergency treatment administered?
- Patient outcome: resolved spontaneously? Required treatment? Admitted?
- Allergy list updated: all documented reactions must be added to the patient's allergy/adverse reaction list in the medical record
- Pharmacy/prescriber notification if ongoing prescription involved
Practice COA Drug Safety Questions
Opterio includes adverse drug reaction questions within COA Pharmacology domain practice, with AI-powered explanations connecting mechanism to clinical presentation.